Welcome to our dedicated page for Astrazeneca Plc SEC filings (Ticker: AZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AstraZeneca PLC (AZN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. AstraZeneca files under Form 20-F for its annual report and uses Form 6-K to furnish current reports on material developments. These filings cover a broad range of topics, including clinical trial data, regulatory approvals, manufacturing investments, insider share transactions and changes in major shareholdings.
For investors following AstraZeneca’s oncology franchise, 6-K exhibits often reproduce detailed press releases on medicines such as Enhertu (trastuzumab deruxtecan), Datroway (datopotamab deruxtecan) and Imfinzi (durvalumab). These documents describe Phase 3 trial designs and endpoints, Breakthrough Therapy Designations, new indications in breast, lung, gastric, endometrial and ovarian cancers, and approvals in key markets. They can help readers understand how specific trials, such as DESTINY-Breast, TROPION, MATTERHORN and others, relate to AstraZeneca’s pipeline and commercial portfolio.
Filings also address Rare Diseases and Respiratory & Immunology, including updates on Koselugo (selumetinib) for neurofibromatosis type 1 and Saphnelo (anifrolumab) for systemic lupus erythematosus. Additional 6-Ks report on large capital projects, such as multi‑billion‑dollar manufacturing investments in Maryland and other US states, and on governance matters like director and senior executive share dealings or notifications of major institutional holdings.
On Stock Titan, these AZN filings are supplemented with AI-powered summaries that explain the key points of each document in plain language. Users can quickly see which filings relate to new indications, safety information, insider transactions (similar to Form 4-style disclosures for US issuers) or strategic investments. Real-time updates from EDGAR ensure that new AstraZeneca 6-Ks and other SEC submissions appear promptly, while AI insights help readers navigate lengthy technical exhibits such as clinical trial descriptions and multi-indication product updates.
AstraZeneca reported its total voting rights and issued share capital. The company states that as at 31 August 2025 there are 1,550,692,963 ordinary shares of US$0.25 each carrying voting rights, with no shares held in treasury. This figure is presented so shareholders can use it as the denominator to determine whether they must notify changes in their holdings under the UK Disclosure and Transparency Rules.
The notice is a routine transparency disclosure and does not include financial results, transactions, or changes to capital structure beyond the voting‑rights count.
AstraZeneca issued a correction to a previously announced TR-1 notification. The Company states that a TR-1 submitted by The Capital Group Companies, Inc. and announced on 26 August 2025 was provided in error and should be disregarded. Shareholders are instead directed to the TR-1 notification relating to Capital Group that AstraZeneca announced on 21 August 2025, available via the referenced RNS link. The notice is administrative and clarifies which prior disclosure is the valid notification.
AstraZeneca PLC furnished a Form 6-K reporting a notification of major holdings showing that The Capital Group Companies, Inc. and its affiliated investment managers crossed the 5% ownership threshold on 20-Aug-2025. The filing shows a resulting position of 77,500,852 shares, representing 5.009591% of voting rights, plus 14,685,540 depository receipts held indirectly (reported as 0.947037% indirect voting rights).
The disclosure explains the asset managers manage these shares on behalf of discretionary client accounts and that neither CGC nor its affiliates hold the shares for their own account. The Form 6-K is a routine, regulatory notification of significant institutional ownership rather than a corporate action by AstraZeneca.
AstraZeneca PLC reported a notification that its Executive Director and Chief Financial Officer, Aradhana Sarin, executed a sale of the company’s ordinary shares on
AstraZeneca PLC received a TR-1 notification showing The Capital Group Companies, Inc. and its affiliates reported a combined holding of 77,682,857 ordinary shares, representing 4.984560% of voting rights as of 14-Aug-2025. Of that total, 14,351,342 are held as depository receipts (ISIN US0463531089), representing 0.925485% of voting rights. The filing clarifies these shares are owned by client accounts under discretionary management across Capital Group entities, not held for the parent companies' own accounts. The notification supplies the chain of controlled undertakings through which the holdings are managed and is signed by AstraZeneca's Company Secretary on 15 August 2025.
AstraZeneca received a TR-1 notification showing The Capital Group Companies, Inc. and its investment management affiliates crossed the 5% voting threshold in AstraZeneca ordinary shares on 11-Aug-2025. The notification reports a resulting total holding of 5.000629% of voting rights, represented by 77,294,699 underlying voting rights and 14,394,421 depository receipts (ISIN US0463531089) accounting for 0.928264% of voting rights. The filing discloses the full chain of controlled undertakings through which the holdings are held and explains these shares are owned by client accounts under discretionary management by Capital Group entities rather than for Capital Group's own account.
H1 2025 results: Total revenue rose 11% CER to $28.0 bn, led by Oncology (+16%) and BioPharmaceuticals. Product Sales were $26.7 bn (+10%), Alliance Revenue $1.3 bn (+38%). Core EPS reached $4.66 (+17%) and reported EPS $3.46 (+32%) as core operating profit advanced 13%.
Q2 2025: Revenue grew 11% CER to $14.5 bn; core EPS $2.17 (+12%). Gross margin 83%; reported operating margin 24% (core 32%). Key brands outperformed: Tagrisso $3.5 bn (+10%), Imfinzi $2.7 bn (+21%), Enhertu $1.3 bn (+38%) while Soliris (-30%) and Brilinta (-21%) declined.
Capital allocation & strategy: Interim dividend increased 3% to $1.03. AZN acquired cell-therapy firm EsoBiotec for up to $1 bn, signed a $110 m upfront AI-drug-discovery deal with CSPC (milestones up to $5.2 bn) and announced a $50 bn US manufacturing/R&D investment, including a new Virginia drug-substance plant.
R&D momentum: 12 positive Phase III readouts (e.g., baxdrostat BaxHTN, Tagrisso FLAURA2) and 19 approvals. Pipeline breadth reinforced by oncology, CVRM and rare-disease advances.
Guidance reaffirmed: 2025 total revenue to grow high-single-digits and core EPS low-double-digits (CER); FX now seen broadly neutral. Core tax rate 18-22%.
FAQ
What is the current stock price of Astrazeneca Plc (AZN)?
What is the market cap of Astrazeneca Plc (AZN)?
